Well no matter who is right about the reason for manipulation out of you and @alcar the great thing is it's clearly evident this stock is under tight control and when things move the stock is tightly wound to spring violently upwards. Absolute peer leading financial performance year after year, undervalued compared to peers on just about every metric and a blockbuster phase 3 trial that is not priced at all despite amazing photographic evidence of efficacy and the drug itself already having FDA approval and well proven safety not to mention an already established and very profitable distribution network. 210 subjects recruited, trial to finish next year and provide results next year as well.
All IMO DYOR
CUV Price at posting:
$10.24 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)